Whelan J - Search Results

1

Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials.

Gelderblom H, Jinks RC, Sydes M, Bramwell VH, van Glabbeke M, Grimer RJ, Hogendoorn PC, McTiernan A, Lewis IJ, Nooij MA, Taminiau AH, Whelan J; European Osteosarcoma Intergroup. Gelderblom H, et al. Among authors: whelan j. Eur J Cancer. 2011 Apr;47(6):895-902. doi: 10.1016/j.ejca.2010.11.036. Epub 2011 Jan 6. Eur J Cancer. 2011. PMID: 21216138

2

Osteosarcoma.

Whelan JS. Whelan JS. Eur J Cancer. 1997 Sep;33(10):1611-8; discussion 1618-9. doi: 10.1016/s0959-8049(97)00251-7. Eur J Cancer. 1997. PMID: 9389923 Review. No abstract available.

3

A pilot study of short-course intensive multiagent chemotherapy in metastatic and axial skeletal osteosarcoma.

Janinis J, McTiernan A, Driver D, Mitchell C, Cassoni AM, Pringle J, Kilby A, Whelan JS; London Bone and Soft Tissue Tumour Service. Janinis J, et al. Among authors: whelan js. Ann Oncol. 2002 Dec;13(12):1935-44. doi: 10.1093/annonc/mdf338. Ann Oncol. 2002. PMID: 12453863 Free article.

4

Single center experience of a new intensive induction therapy for ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties.

Strauss SJ, McTiernan A, Driver D, Hall-Craggs M, Sandison A, Cassoni AM, Kilby A, Michelagnoli M, Pringle J, Cobb J, Briggs T, Cannon S, Witt J, Whelan JS. Strauss SJ, et al. Among authors: whelan js. J Clin Oncol. 2003 Aug 1;21(15):2974-81. doi: 10.1200/JCO.2003.04.106. J Clin Oncol. 2003. PMID: 12885818

5

Carboplatin-based chemotherapy for refractory and recurrent Ewing's tumours.

Whelan JS, McTiernan A, Kakouri E, Kilby A; London Bone and Soft Tissue Tumour Service. Whelan JS, et al. Pediatr Blood Cancer. 2004 Sep;43(3):237-42. doi: 10.1002/pbc.20107. Pediatr Blood Cancer. 2004. PMID: 15266407

6

Late relapse of osteosarcoma: implications for follow-up and screening.

Strauss SJ, McTiernan A, Whelan JS. Strauss SJ, et al. Among authors: whelan js. Pediatr Blood Cancer. 2004 Nov;43(6):692-7. doi: 10.1002/pbc.20154. Pediatr Blood Cancer. 2004. PMID: 15390283

7

A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.

McTiernan A, Meyer T, Michelagnoli MP, Lewis I, Whelan JS. McTiernan A, et al. Pediatr Blood Cancer. 2006 Mar;46(3):345-50. doi: 10.1002/pbc.20562. Pediatr Blood Cancer. 2006. PMID: 16206197 Clinical Trial.

8

Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.

Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O, Michon J, Zoubek A, Juergens H, Craft A. Juergens C, et al. Among authors: whelan j. Pediatr Blood Cancer. 2006 Jul;47(1):22-9. doi: 10.1002/pbc.20820. Pediatr Blood Cancer. 2006. PMID: 16572419

9

High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours.

McTiernan A, Driver D, Michelagnoli MP, Kilby AM, Whelan JS. McTiernan A, et al. Among authors: whelan js. Ann Oncol. 2006 Aug;17(8):1301-5. doi: 10.1093/annonc/mdl108. Epub 2006 Jun 16. Ann Oncol. 2006. PMID: 16782749 Free article.

10

A Phase II Nonrandomised Open-Label Study of Liposomal Daunorubicin (DaunoXome) in Advanced Soft Tissue Sarcoma.

McTiernan A, Whelan J, Leahy M, Woll PJ. McTiernan A, et al. Among authors: whelan j. Sarcoma. 2006;2006(1):41080. doi: 10.1155/SRCM/2006/41080. Sarcoma. 2006. PMID: 17040090 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,139 results

Search Page